Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 3 Clinical trials applying silymarin to patients with alcoholic liver disease

From: The potential of silymarin for the treatment of hepatic disorders

Study

Silymarin

Control

Weighta

WMD (fixed)

 

N

Mean (SD)

N

Mean (SD)

%

95 % CI

DiMario et al., 1981 [70]

15

25.40 (15.60)

14

50.60 (24.30)

3.38

−25.20 [−40.18, −10.22]

Salmi et al., 1982 [71]

47

38.20(15.99)

50

51.20(24.99)

11

−13.00 [−21.30, −4.70]

Feher et al., 1989 [72]

17

22.80(5.10)

19

31.30(4.50)

76.01

−8.50 [−11.66, −5.34]

Müzes et al., 1990 [73]

10

28.00(11.00)

20

52.00(13.00)

9.6

−24.00 [−32.88, −15.12]

Total (95 % CI)

89

 

103

 

100

−11.05 [−13.80, −8.29]

  1. aWeighted mean differences of aspartate aminotransferase (AST) serum levels comparing control patients and patients receiving silymarin after the end of treatment
  2. Test for heterogeneity: Chi2 = 14.31, df = 3 (P = 0.003), I2 = 79.0 %
  3. Test for overall effect: Z = 7.86 (P < 0.00001)